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Abstract
Background: Epidemiological and observational studies have established that high-density lipoprotein cholesterol
(HDL-C) is an independent negative cardiovascular risk factor. However, simple measurement of HDL-C levels is no
longer sufficient for cardiovascular risk assessment. Therefore, there is a critical need for novel non-invasive
biomarkers that would display prognostic superiority over HDL-C. Cell surface ecto-F1-ATPase contributes to several
athero-protective properties of HDL, including reverse cholesterol transport and vascular endothelial protection.
Serum inhibitory factor 1 (IF1), an endogenous inhibitor of ecto-F1-ATPase, is an independent determinant of HDL-C
associated with low risk of coronary artery disease (CAD). This work aimed to examine the predictive value of serum
IF1 for long-term mortality in CAD patients. Its informative value was compared to that of HDL-C.
Method: Serum IF1 levels were measured in 577 male participants with stable CAD (age 45–74 years) from the
GENES (Genetique et ENvironnement en Europe du Sud) study. Vital status was yearly assessed, with a median
follow-up of 11 years and a 29.5 % mortality rate. Cardiovascular mortality accounted for the majority (62.4 %) of
deaths.
Results: IF1 levels were positively correlated with HDL-C (rs = 0.40; P < 0.001) and negatively with triglycerides (rs = −0.
21, P < 0.001) and CAD severity documented by the Gensini score (rs = −0.13; P < 0.01). Total and cardiovascular
mortality were lower at the highest quartiles of IF1 (HR = 0.55; 95 % CI, 0.38–0.89 and 0.50 (0.28–0.89), respectively) but
not according to HDL-C. Inverse associations of IF1 with mortality remained significant, after multivariate adjustments
for classical cardiovascular risk factors (age, smoking, physical activity, waist circumference, HDL-C, dyslipidemia,
hypertension, and diabetes) and for powerful biological and clinical variables of prognosis, including heart rate,
ankle-brachial index and biomarkers of cardiac diseases. The 10-year mortality was 28.5 % in patients with low IF1
(<0.42 mg/L) and 21.4 % in those with high IF1 (≥0.42 mg/L, P < 0.02).
Conclusions: We investigated for the first time the relation between IF1 levels and long-term prognosis in CAD
patients, and found an independent negative association. IF1 measurement might be used as a novel HDL-related
biomarker to better stratify risk in populations at high risk or in the setting of pharmacotherapy.
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Background
A low level of high density lipoprotein-cholesterol
(HDL-C) is a robust and independent risk factor of cor-
onary artery diseases (CAD) as it represents the choles-
terol content of HDL particles [1–4]. To date, however,
it has proved difficult to successfully reduce cardiovascu-
lar risk with HDL-C raising drugs such as niacin or in-
hibitors of cholesteryl ester transfer protein [5–7].
Furthermore, Mendelian randomization studies of com-
mon genetic variants for HDL-C are inconsistent in their
support of a causal relationship between HDL-C level
and CAD [8]. These observations underline the potential
limitation of using HDL-C levels (a static mass based
measurement) for assessing CAD risk or for evaluating
the therapeutic efficiency of treatments aimed at HDL.
In fact, only 5 % of the total HDL-C is derived from ac-
tual macrophage cholesterol efflux [9], indicating that
HDL-C is a poor surrogate of reverse cholesterol trans-
port (RCT), the postulated main anti-atherogenic effect
of HDL. Further, HDL cholesterol content does not rep-
resent other important anti-atherogenic HDL properties,
such as anti-inflammatory, anti-thrombotic, anti-oxidant,
vasorelaxant, and cytoprotective effects [10, 11]. Thus, a
great clinical need exists for HDL-related biomarkers that,
more directly than HDL-C (HDL-C “quantity”), reflect the
functionality of HDL (HDL “quality”) [11].
A few years ago, while studying the last steps of RCT,
we identified plasma membrane ecto-F1-ATPase as a
high affinity receptor for HDL apolipoprotein A-I
(apoA-I), triggering HDL uptake by the liver [12]. More
recently still, ecto-F1-ATPase was identified to also be
an apoA-I receptor involved in HDL-mediated endothe-
lial cell survival and HDL transcytosis through aortic
endothelial cells [13, 14]. Ecto-F1-ATPase is identical to
the catalytic F1 domain of the mitochondrial F1FO-ATP-
synthase, which synthesizes ATP in response to proton
flux from the inter-membrane space to the mitochon-
drion matrix [15]. In acidosis conditions, when the pro-
ton flux is impaired, the ATP-synthase complex turns
into an ATP-hydrolytic enzyme. A mitochondrial pep-
tide, inhibitory factor 1 (IF1), then binds to the complex,
inhibiting its hydrolytic activity and preventing the
breakdown of the ATP in cellular pools [15]. Experimen-
tally, exogenous IF1 can also inhibit the ATPase activity
of plasma membrane ecto-F1-ATPase and block HDL
endocytosis in hepatocytes and endothelial cells [12, 14].
Unexpectedly, we have recently found IF1 to be
present in human serum, its concentration following a
normal distribution in the general population [16]. Cir-
culating IF1 was found to be associated with HDL-C,
suggesting it could be a biomarker indicative of F1-
ATPase-mediated HDL functions [16, 17]. In the context
of a large case-control study on CAD, the GENES study,
IF1 was found to be negatively associated with CAD
[17]. This association was independent of HDL-C and of
other classical cardiovascular risk factors [17]. These
conclusions were drawn from association studies in a
cross-sectional design. However, the vital status of all
stable CAD patients from this cohort was available with
a median follow-up of 11 years. Therefore, the aim of
the present study was to investigate the association of
IF1 serum level with mortality in CAD patients from the
GENES study. This association was compared to that of
HDL-C.
Methods
Study participants
The Genetique et ENvironnement en Europe du Sud
(GENES) study is a case-control study designed to inves-
tigate the role of gene–environment interactions in the
occurrence of CAD [18]. From 2002 to 2004, we have
prospectively recruited 834 male patients aged between 45
and 74 years, living in the Toulouse area (south-western
France), admitted in the department of Cardiology of the
Toulouse University Hospital, and referred for evaluation
and management of stable CAD. Stable CAD was defined
by a previous history of acute coronary syndrome, a previ-
ous history of coronary artery revascularization, a docu-
mented myocardial ischemia, a stable angina, or the
presence at the coronary angiography of a coronary
stenosis of ≥ 50 % of luminal narrowing. Patients who
had an acute coronary episode during the past 7 days
were not included in the study because they were not
considered as stable. In the present analysis, we only
took into account the first 577 patients in whom total
serum IF1 was measured and complete data were
available.
Assessment of the vital status
Vital status on December 31, 2013, was obtained for each
participant through the national database (“RNIPP”),
which records annual all deaths occurring in the French
population (http://cesp.vjf.inserm.fr/svcd). Vital status was
assessed yearly, with a median follow-up of 11 years. All
dates and causes of death were obtained for participants
who died during the follow-up period. Main and associ-
ated causes of death were provided by the French National
Institute of Health Research (CépiDc-INSERM), which
systematically collects and codes (using the International
Classification of Diseases coding system) data recorded on
death certificates. Death from a cardiovascular cause dur-
ing follow-up was assessed by a committee of four medical
doctors, every time cardiovascular disease was reported as
the main cause of death, or when it was mentioned as an
associated cause, if the main cause was a plausible compli-
cation of cardiovascular disease. Authorizations to use
these data were obtained in accordance with French law
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(Commission nationale de l'informatique et des libertés
(CNIL): authorization 355152v1, September 3, 2008).
Measured parameters
Age, environmental characteristics, and information on
cardiovascular risk factors were collected through stan-
dardized face-to-face interviews, performed by a single
physician. Smoking status was classified as current
smokers, smokers having quit for more than 3 years, and
non-smokers. Among current smokers, cigarette con-
sumption was estimated with the pack-year quantifica-
tion and recorded as the average number of cigarettes
per day. Alcohol consumption was assessed using a typ-
ical week pattern. The total amount of pure alcohol con-
sumption was calculated as the sum of different types of
drinks and was expressed as grams per day. Physical ac-
tivity was investigated through a standardized question-
naire [19] and categorized into three levels as no
physical activity, moderate physical activity during 20 mi-
nutes no more than once a week, and high physical ac-
tivity during 20 minutes, at least twice a week. Presence
of dyslipidemia, diabetes mellitus or hypertension was
assessed from the subjects’ current treatments. Past
medical history was collected and, for cases, was also
checked in the patients’ medical files. Medications at dis-
charge were also considered in patients.
A trained physician performed physical examinations,
using standard measurement methods. Anthropometri-
cal measurements including waist circumference, height,
and body weight were performed and body mass index
(BMI, kg/m2) was calculated. Blood pressure and resting
heart rate were measured with an automatic sphygmo-
manometer (OMRON 705 CP). Measurements were per-
formed after a minimum of 5 minutes rest; average
values from two different measurements were recorded
for further analysis. Ankle-brachial index was deter-
mined as previously described, and a value of ≤ 0.9 was
considered abnormal [20].
Assessment of CAD severity and extension and
estimation of cardiac function
Coronary artery stenoses of ≥ 50 % luminal narrowing
were considered significant. Diffusion of coronary artery
disease lesions were assessed by calculating the Gensini
Score, based on data from coronary angiography [21–
23]. Left ventricular ejection fraction (LVEF) was
assessed by contrast ventriculography using an isotopic
method, and/or by echocardiography.
Laboratory assays
Blood was collected after an overnight fast. Serum sam-
ple aliquots were subsequently stored at −80 °C until
biological analyses. The following biomarkers were
assayed with enzymatic reagents on automated analyzers
(Hitachi 912 and Cobas 8000, Roche Diagnostics,
Meylan, France): serum total cholesterol, HDL-C, tri-
glycerides, fasting glucose, high-sensitivity C reactive
protein (hs-CRP), N-terminal pro-brain natriuretic pep-
tide (NT-proBNP), and high-sensitivity cardiac troponin
T (hs-TnT). Lipoprotein(a) was assayed with an immu-
noturbidimetric method on an automated analyzer
(Roche Diagnostics, Meylan, France) and estimated
glomerular filtration rate (eGFR) was calculated using
the abbreviated Modification of Diet in Renal Disease
Study equation [18]. Serum IF1 concentration was mea-
sured using a competitive ELISA immuno-assay previ-
ously developed in our laboratory [16] and for which
intra-assay and inter-assay variability ranged from 6 % to
7 % and several other tests were performed including ab-
sence of interference with apolipoproteins A-I and A-II
or resistance to freezing and thawing [17].
HDL measurement by nuclear magnetic resonance (NMR)
spectroscopy
HDL particle concentration and size were measured by
NMR spectroscopy using the AXINON® lipoFIT®-S100
test system (Numares AG, Regensburg, Germany) in 212
randomly selected CAD patients from the initial sample.
Briefly, 1H NMR spectra were recorded at a temperature
of 310 K on a shielded 600 MHz Avance III HD NMR
spectrometer (Bruker Biospin) with a 5 mm triple reson-
ance TXI probe head including a deuterium lock chan-
nel, atm unit, and a z-gradient coil. Lipoprotein analysis
was conducted via deconvolution of the broad methyl
group signal at approximately 0.9–0.8 ppm, delivering
the concentrations of lipoprotein particles as well as the
average particle size. In addition, a custom algorithm
was used to mathematically remove a signal derived
from gel separator blood collection tubes interfering
with the calculation. This algorithm is not part of the
CE-marked lipoFIT®-S100 software. In this study, the
concentrations of total HDL particles (reported in μmol/
L) as well as the average HDL particle size (reported in
nm) are used.
Statistical analyses
Continuous variables are displayed as means and
standard deviations. Categorical variables are pre-
sented as proportions. We first described and com-
pared the characteristics of participants according to
vital status. Categorical variables were compared
between groups using the χ2 test (or Fisher’s exact
test when necessary). The Student’s t test was used to
compare the distribution of continuous data. A
Mann–Whitney’s test (or logarithmic transformation
of the variable when necessary) was performed when
distribution departed from normality, or when homo-
scedasticity was rejected. Spearman rank correlations
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were used to test the associations of IF1 and HDL-C
with cardiovascular risk factors, severity, extension,
and estimation of cardiac function of the disease.
Cumulative survival of patients were determined by
the Kaplan–Meier method and compared using the
Log-rank test for the individual endpoints of all-cause
mortality. The relation between baseline variables and
mortality was assessed using Cox proportional haz-
ards regression analysis. We tested the proportionality
assumption using cumulative sums of martingale-
based residuals. We performed regression analyses
with polynomial models (quadratic and cubic) to
examine for possible non-linear relations between
continuous variables and mortality. Cox regression
analyses were performed first without any adjustment
for co-variables and, second, with adjustment on
classical cardiovascular risk factors (age, treatments
for dyslipidemia, hypertension and diabetes, smoking
and HDL-C) and extended cardiovascular risk factors
(classical risk factors plus waist circumference, phys-
ical activity, CRP, eGFR, and duration of CAD).
Further adjustments were successively performed on
other biomarkers of cardiac diseases (NT-proBNP and
hs-TnT) as well as non-invasive and invasive clinical
parameters related to the severity and extension of
the disease and cardiac function (heart rate, ABI,
LVEF and Gensini score). Finally, the association of
mortality with IF1 according to median cutoff of
serum concentration was analyzed. All statistical ana-
lyses were carried out using the SAS statistical soft-
ware package 9.4 (SAS Institute, Cary, NC). All tests
were considered significant at a P value < 0.05.
Table 1 Clinical and biological characteristics in coronary artery disease patients when they were first included in the GENES study
Alive (n = 407) Dead (n = 170) P
Age, years 59.5 (7.8) 62.9 (8.0) 0.03
School, years of education 9.7 (3.0) 9.2 (2.6) 0.03b
Smoking, pack year 31.3 (31.1) 49.3 (44.1) 0.001b
Alcohol, g/day 28.4 (31.6) 28.7 (29.6) 0.93
Physical activity (high level), % 14.3 5.3 0.003
Treatment for diabetes, % 19.4 36.5 0.001
Treatment for dyslipidemia, % 67.6 56.5 0.02
Treatment for hypertension, % 42.7 50.0 0.12
BMI, kg/m2 27.3 (3.8) 27.7 (4.4) 0.27
Waist circumference, cm 97.9 (10.0) 101.5 (12.7) 0.001
Systolic blood pressure, mm Hg 139.2 (20.1) 139.8 (22.0) 0.77
Heart rate, beats/min 62.2 (10.6) 67.1 (13.3) 0.001a
Fasting glucose, mmoL/L 5.69 (1.58) 6.41 (2.72) 0.06b
Triglycerides, g/L 1.66 (0.88) 1.57 (0.80) 0.17a
Total cholesterol, g/L 2.01 (0.41) 1.94 (0.43) 0.06
LDL-C, g/L 1.25 (0.35) 1.20 (0.39) 0.13
HDL-C, g/L 0.43 (0.12) 0.43 (0.11) 0.42
Lipoprotein(a)≥ 0.30 vs. < 0.30 g/L, % 55.8 47.7 0.08
eGFR < 30 mL/min, % 0.5 4.7 0.002c
hs-CRP≥ 5 mg/L vs. < 5 mg/L, % 51.6 64.1 0.006
hs-TnT, pg/mL 145.9 (386.2) 198.1 (469.1) 0.002b
NT-proBNP, pg/mL 383.3 (683.1) 1253.9 (2347.5) 0.001b
ABI ≤ 0.9, % 29.7 47.1 0.001
LVEF≥ 50 %, % 77.2 49.4 0.001
Gensini score 43.8 (37.3) 57.3 (46.3) 0.003a
Duration of coronary artery disease, months 33.4 (57.2) 57.6 (73.2) 0.001b
IF1, mg/L 0.44 (0.12) 0.41 (0.13) 0.03
Data are expressed in mean (SD) or %
BMI body mass index, eGFR estimated Glomerular Filtration Rate, hs-CRP high-sensitivity C-Reactive Protein, hs-TnT high-sensitivity cardiac troponin T, NT-proBNP
N-terminal pro-brain natriuretic peptide, ABI Ankle-brachial index, LVEF Left Ventricular Ejection Fraction
alog transformed data, bWilcoxon–Mann–Whitney test, cFischer’s exact test
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Results
Bio-clinical parameters according to vital status
In the GENES study, a cohort of 832 CAD patients was
constituted between 2002 and 2004. IF1 measurements
were available for a subsample of the first 651 patients
from this initial cohort. During follow-up, the vital status
of patients was assessed yearly. The median follow-up
period was 11 years (mean: 9.9 years). Complete clinical
and biological data, including IF1 measurements, were
available for 577 patients (70 % of the whole cohort).
Among them, by December 2013, 170 deaths had been re-
corded during follow-up, giving a mortality rate of 29.5 %,
similar to that observed in the whole cohort (29.6 %), and
a mean annual death rate of 2.9 % (95 % CI, 1.6–4.4; P <
0.01). Cardiovascular mortality accounted for the majority
(62.4 %) of deaths recorded, whereas cancers accounted
for 17.1 %. Other causes amounted to 20.5 %.
There were noticeable differences between cohort pa-
tients who died and those who survived during follow-
up in the values for data determined at the start of the
study (Table 1). Patients who died were older and had
suffered with CAD for longer. They tended to be of a
lower educational level and to have been less physically
active. Among classical risk factors, tobacco consump-
tion and treatment for diabetes were more frequent in
patients who subsequently died than in survivors and
average fasting glycaemia tended to be higher. Con-
versely, lipid-lowering therapy was more frequent in pa-
tients that survived (Table 1). Statins had been
administered to 62.2 % of surviving patients versus
51.2 % of those who had died (Additional file 1: Table
S1). Systolic blood pressure was not different between
the two groups (Table 1). Beta-blockers and anti-platelet
agents (acetylsalicylic acid or clopidogrel) were more fre-
quently administered among surviving patients than in
deceased ones (Additional file 1: Table S1), probably
reflecting treatment efficacy. The reverse situation was
observed for angiotensin converting enzyme (ACE) in-
hibitors, more frequently found in deceased patients.
ACE inhibitors are particularly administered to patients
presenting signs of congestive heart failure; our data
may indicate a higher prevalence of this condition
among patients having deceased.
Among the clinical variables, mortality was associated
with higher waist circumference, higher heart rate, and a
higher proportion of a pejorative ankle-brachial index
(ABI), but also with lower LVEF, since only 49 % of dead
patients had LVEF ≥ 50 % versus 77 % in survivors. Le-
sion severity, as documented by the angiographic Gen-
sini score, was more pronounced in deceased patients.
Among metabolic parameters, LDL-C or HDL-C were
not different between the two groups but patients who
died had lower IF1 concentrations. IF1 concentrations
were not significantly different between statin-treated or
non-treated patient subgroups (interaction statin × IF1,
P = 0.68), either deceased or still alive (not shown).
NT-proBNP and hs-TnT, two biomarkers associated
with myocardial damages, were higher in patients who
died. An elevated hs-CRP, documenting an inflammatory
condition, was more frequent among deceased patients.
Finally, severe renal failure, as documented by a glom-
erular filtration rate below 30 mL/min, was more fre-
quent in deceased patients.
Correlations between IF1, HDL-C, cardiovascular risk
factors, and variables
As commonly reported, HDL-C was found to be nega-
tively correlated with several different cardiovascular risk
markers. In particular, there was a negative correlation
with those markers associated with metabolic syndrome:
triglycerides, systolic blood pressure, BMI, and waist cir-
cumference (Table 2). HDL-C was also inversely related
to CAD severity, as documented by the Gensini score.
HDL-C was positively associated with alcohol consump-
tion and physical activity and negatively associated to
cardiac biomarkers indicative of myocardial damages
(NT-proBNP and hs-TnT) and to hs-CRP, reflecting an
inflammatory condition.
Serum IF1 was positively correlated with HDL-C and
negatively with triglycerides (Table 2), as we have previ-
ously reported in control subjects taken from the general
population [17]. However, unlike HDL-C, IF1 was not
correlated with blood pressure and alcohol consumption
(Table 2). IF1 was negatively associated with hs-CRP and
NT-proBNP, but not with hs-TnT. A positive association
with LVEF and a negative one with the severity of CAD
(Gensini score) were also recorded. A negative associ-
ation with heart rate was observed close to significance
(Table 2). Furthermore, IF1 was also related to eGFR.
Thus, although correlated to HDL-C, IF1 displays spe-
cific associations with clinical variables.
The concentrations of total HDL particles (HDL-P, re-
ported in μmol/L) as well as the average HDL particle
size (reported in nm) were measured in 212 randomly
selected CAD patients from the initial sample (mean,
26.43 μmol/L (SD 5.5) and 8.87 nm (SD 0.34), respect-
ively). As reported in Additional file 1: Table S2, IF1 dis-
plays a positive association with HDL-C (rs = 0.35, P <
0.001), similar to that observed in the first 577 CAD pa-
tients (rs = 0.40, P < 0.001, Table 2). Interestingly, IF1 was
moderately positively correlated with HDL-P and HDL
particle size (Additional file 1: Table S2, rs = 0.30, P <
0.001 and rs = 0.21, P < 0.01, respectively). HDL-C was
even more strongly positively associated with those
NMR HDL measurements (rs = 0.72, P < 0.001 and rs =
0.48, P < 0.001, respectively). Finally, HDL-P was not
correlated with HDL particle size (rs = −0.04, P = 0.53),
as previously reported in other studies [24, 25].
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Association of IF1 with mortality in CAD patients
The values of HDL-C and IF1 were divided into quar-
tiles in order to test their impact on mortality that had
occurred from any cause at any time during follow-up.
No difference in death rates was seen across the quar-
tiles of HDL-C distribution (Table 3). Conversely, death
rates declined from 36.7 % to 22.9 % between quartiles 1
and 4 of IF1 distribution (P = 0.007). In the IF1 upper
quartile, the hazard ratio (HR) was 0.55 (95 % CI, 0.38–
0.89) for total mortality and 0.50 (95 % CI, 0.28–0.89)
for cardiovascular mortality (Table 3). IF1 level was not
associated to cancer mortality (Table 3).
Table 2 Correlation between IF1, HDL-C, and other cardiovascular risk factors in coronary artery disease patients
IF1 (mg/L) HDL-C (g/L)
Age, years −0.10 (−0.18 to −0.02)* 0.10 (0.02 to 0.18)*
Smoking, cig/day 0.02 (−0.05 to 0.11) −0.08 (−0.16 to 0.01)
Alcohol, g/day 0.03 (−0.05 to 0.11) 0.16 (0.08 to 0.23)***
Physical activity score 0.15 (0.07 to 0.23)*** 0.13 (0.05 to 0.21)**
BMI, kg/m2 −0.05 (−0.13 to 0.04) −0.17 (−0.25 to −0.09)***
Waist circumference, cm −0.09 (−0.17 to −0.01)* −0.16 (−0.24 to −0.08)***
SBP, mm Hg 0.01 (−0.09 to 0.08) 0.12 (0.04 to 0.20)***
Heart rate, beats/mn −0.07 (−0.16 to −0.01) 0.03 (−0.05 to 0.11)
Glucose, mmoL/L −0.01 (−0.9 to 0.07) −0.11 (−0.19 to −0.02)*
Triglycerides, g/L −0.21 (−0.28 to −0.13)*** −0.41 (−0.48 to −0.34)***
Total cholesterol, g/L 0.08 (0.01 to 0.16)* 0.22 (0.14 to 0.30)***
HDL-C, g/L 0.40 (0.33 to 0.46)***
eGFR, mL/min 0.09 (0.01 to 0.17)* −0.01 (−0.08 to 0.08)
hs-CRP, mg/L −0.14 (−0.22 to −0.06)*** −0.19 (−0.27 to −0.11)***
hs-TnT, pg/ml −0.07 (−0.15 to 0.01) −0.15 (−0.23 to −0.07)***
NT-proBNP, pg/mL −0.18 (−0.26 to −0.10)*** −0.11 (−0.18 to −0.02)*
LVEF, % 0.19 (0.11 to 0.27)*** 0.05 (−0.03 to 0.14)
Gensini score −0.13 (−0.20 to −0.04)** −0.15 (−0.23 to −0.07)***
Spearman rank correlation (95 % confidence interval).*P < 0.05, **P < 0.01, ***P < 0.001
BMI body mass index, SBP systolic blood pressure, hs-CRP high-sensitivity C-Reactive Protein, hs-TnT high-sensitivity cardiac troponin T, NT-proBNP N-terminal
pro-brain natriuretic peptide, LVEF left ventricular ejection fraction
Table 3 Death rate according to HDL-C and IF1 and association with mortality
HDL-C
Q1 Q2 Q3 Q4 P for trend
(n = 145) (n = 151) (n = 132) (n = 143)
Death rates, % 25.5 34.4 29.5 29.4 0.65
Hazard ratio for total mortality, 95 % CI 1 1.42 (0.93–2.17) 1.18 (0.75–1.84) 1.18 (0.76–1.83) 0.72
Hazard ratio for cardiovascular mortality, 95 % CI 1 1.45 (0.88–2.57) 1.12
(0.60–2.07)
0.95
(0.50–1.80)
0.67
IF1
Q1 Q2 Q3 Q4 P for trend
(n = 147) (n = 141) (n = 145) (n = 144)
Death rates, % 36.7 31.2 26.9 22.9 0.007
Death rate per-person years, number of deaths per 1000 person-years 38.8 32.2 27.2 23.2 0.007
Hazard ratio for total mortality, 95 % CI 1 0.83 (0.56–1.23) 0.69 (0.45–1.04) 0.55 (0.38–0.89) 0.008
Hazard ratio for cardiovascular mortality, 95 % CI 1 0.51 (0.28–0.94) 0.65 (0.38–1.12) 0.50 (0.28–0.89) 0.03
Hazard ratio for cancer mortality, 95 % CI 1 1.24 (0.51–2.99) 0.53 (0.18–1.57) 0.53 (0.18–1.58) 0.12
Quartiles for HDL-C: 0.38, 0.42, 0.48 g/L
Quartiles for IF1: 0.35, 0.41, 0.49 mg/L
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In multivariable analyses, adjustments were made for
multiple clinical or biological variables associated with
mortality. Table 4 illustrates the HR of IF1 quartiles re-
garding total mortality, using different models. Associ-
ation of elevated IF1 with decreased mortality was
significant after adjustments on classical cardiovascular
risk factors, including age, smoking, and treatments for
dyslipidemia, hypertension, and diabetes (model 1, HR
0.61 (95 % CI, 0.39–0.94) for upper quartile). This
remained true even after introduction of obesity, phys-
ical activity, HDL-C, hs-CRP, glomerular filtration rate,
and disease duration (model 2, HR 0.54 (95 % CI, 0.33–
0.88) for upper quartile). Further adjustments on cardiac
biomarkers (model 3, HR 0.57 (95 % CI, 0.35–0.92)) or
on clinical markers associated with cardiovascular mor-
tality (model 4, HR 0.61 (95 % CI, 0.37–0.99)) had little
effects on the association between IF1 and mortality.
Similar trends were observed with cardiovascular mor-
tality (not shown). Although analyses are presented
using quartile distribution of IF1, significant associations
with mortality were also evident when considering IF1
as a continuous variable. Indeed, the unadjusted HR for
total mortality per 1-SD increase in IF1 was 0.84 (95 %
CI, 0.71–0.98). Similar values were measured after ad-
justments on classical risk factors (HR 0.83, 95 % CI,
0.69–0.99).
Survival of CAD patients as a function of IF1
concentrations
Kaplan–Meier survival curves for the follow-up period
were established around the median value of serum IF1
concentration (Fig. 1). Differences in mortality rates were
evident depending on IF1 levels. After 10 years, mortality
rate was 28.5 % in patients with low IF1 (<0.42 mg/L) and
21.4 % in those with high IF1 (P < 0.02).
Discussion
In the present study, an average follow-up of 11 years of
the vital status of CAD patients revealed that high circu-
lating levels of IF1, but not HDL-C, are negatively
associated with all-cause and cardiovascular disease
mortality. For IF1, this remained true even after adjust-
ments for multiple cardiovascular risk factors associated
with mortality, including HDL-C and biomarkers of car-
diac diseases such as NT-proBNP and Hs-TnT.
The fact that HDL-C was not associated with mortality
is consistent with other studies showing that the associ-
ation of HDL-C with cardiovascular mortality is weak-
ened in patients with CAD [26, 27]. One possible
hypothesis is that the protective functions of HDL parti-
cles are affected in CAD patients [28]. This would mean
that measurement of HDL-C would not accurately re-
flect the functionality of HDL particles. Indeed, as ob-
served in our study population, CAD patients display
features of metabolic syndrome with moderate hypertri-
glyceridemia. In the long term, this condition alters the
lipid and proteome composition of HDL particles, lead-
ing to impaired vascular protective properties [28].
IF1 was significantly and inversely associated with
mortality in CAD patients independently of several
established risk factors and even after further adjust-
ments for biomarkers of cardiac diseases (NT-proBNP,
hs-TnT) or clinical parameters associated to cardiovas-
cular complications (ABI, heart rate). This indicates that
IF1 level would reflect a biological process not captured
by classical cardiovascular risk factors or bio-clinical var-
iables and current biomarkers of cardiac functions.
Mitochondrial IF1 has been reported to be over-
expressed in cancer cells and tumors, being possibly in-
volved in cell survival and proliferation through activa-
tion of aerobic glycolysis and reactive oxygen species
signaling [29, 30]. Analysis of tumor expression of cellu-
lar IF1 in cohorts of breast cancer patients revealed its
relevance as a predictive marker for clinical outcome
[30]. In the present study, serum IF1 level was not asso-
ciated with cancer mortality, suggesting that circulating
IF1 does not reflect its mitochondrial function in meta-
bolic reprogramming and cell survival. However, evalu-
ation of serum IF1 in cancer epidemiology cohorts
might help to better evaluate its relevance in cancer pre-
diction and prognosis.
At present, it is only possible to hypothesize on the
mechanisms linking IF1 and cardiovascular mortality
and on the reciprocal relationships between circulating
IF1 and HDL markers, including HDL-C, HDL particle
size, and HDL-P. Bearing in mind that exogenous re-
combinant IF1 reduces HDL endocytosis in hepatocytes
and perfused rat livers [12], circulating IF1 might ac-
tively slow down hepatic HDL holoparticle uptake in
vivo, which would translate into increased levels of
Table 4 Risk of mortality as a function of IF1 levels in coronary
artery disease patients
Q1 Q2 Q3 Q4
(n = 147) (n = 141) (n = 145) (n = 144)
HR (95 % CI) HR (95 % CI) HR (95 % CI)
Model 1 1 0.88 (0.59–1.32) 0.77 (0.51–1.16) 0.61 (0.39–0.94)
Model 2 1 0.90 (0.59–1.36) 0.70 (0.45–1.08) 0.54 (0.33–0.88)
Model 3 1 0.81 (0.53–1.24) 0.73 (0.47–1.12) 0.57 (0.35–0.92)
Model 4 1 1.03 (0.67–1.56) 0.77 (0.50–1.20) 0.61 (0.37–0.99)
Quartiles for IF1: 0.35, 0.41, 0.49 mg/L
HR (95 % CI): Hazard Ratio (95 % confidence interval)
Model 1: adjusted for classical cardiovascular risk factors (age, smoking,
treatments for dyslipidemia, hypertension and diabetes)
Model 2: adjusted for extended cardiovascular risk factors (Model 1 + physical
activity, waist circumference, HDL-C, hs-CRP and eGFR and duration of CAD)
Model 3: model 2 plus NT-proBNP and hs-TnT
Model 4: model 2 plus heart rate and ankle-brachial index
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HDL-C, HDL-P, and HDL particle size. However, this
raises the question of how reducing HDL catabolism
might be beneficial against atherosclerosis. Slowing
down HDL catabolism might prolong the residence time
of HDL particles, enabling them to exert their beneficial
anti-atherosclerotic properties (e.g., anti-inflammatory,
anti-thrombotic, anti-oxidant, vasorelaxant, and cytopro-
tective effects) on the vascular wall. Conversely, this
might not have a major negative impact on the whole
process of RCT because, in humans, the final steps (liver
uptake) occur not only through HDL uptake but also
through low-density lipoprotein uptake following lipid
transfers between lipoproteins [31]. An alternative hy-
pothesis for the negative association between serum IF1
and CAD risk is that IF1 is released from the plasma
membrane where it constitutively binds to ecto-F1-
ATPase. Under this hypothesis, elevated IF1 might actu-
ally reflect increased functional activity of ecto-F1-
ATPase as stimulated by apoA-I. This view is supported
by recent studies reporting that endogenous IF1 is
expressed at the plasma membrane of different cell lines,
including hepatocytes, where it constitutively inhibits
ecto-F1-ATPase activity [32–34]. One hypothesis is that
apoA-I, which competes with IF1 for binding sites on
ecto-F1-ATPase [12–15], contributes to the release of
ecto-IF1 from ecto-F1-ATPase. This would subsequently
promote extracellular ADP production and P2Y13-medi-
ated HDL endocytosis, of which activation has been re-
ported to be athero-protective in mice [15, 35]. In
addition, on endothelial cells, stimulation of ecto-F1-
ATPase activity by apoA-I contributes to HDL-mediated
endothelial protection [13, 14]. Therefore, circulating
IF1 may participate in the complex negative relationship
between HDL and atherosclerosis. Further studies asses-
sing associations between IF1 and other HDL markers,
such as HDL particle size, concentration and functions,
will bring new insight into the relationship between IF1
and HDL turnover, remodeling, and beneficial anti-
atherosclerotic properties.
In addition to HDL markers, IF1 correlated negatively
with heart rate and NT-proBNP, and positively with
LVEF, suggesting that serum IF1 might also reflect myo-
cardial function. In this context, part of circulating IF1
might originate from cardiomyocyte mitochondria.
Interestingly, preconditioning experiments have demon-
strated that, in ischemic conditions, IF1 is actively re-
cruited to mitochondrial F1FO ATP-synthase to block
the massive breakdown of cellular ATP pools [15]. Ac-
cordingly, hypoxia-inducible factor 1 α was shown to
regulate transcriptional levels of IF1 [36]. One could
hypothesize that increased serum IF1 would indicate op-
timal cardiomyocyte function. Interestingly, IF1 was not
correlated to hs-TnT, suggesting again that low IF1
levels would be rather related to myocardial dysfunction
than to the extent of necrosis.
Besides the biological markers discussed above and the
clinical variables related to CAD severity, our study
identifies other individual parameters associated to mor-
tality in CAD patients. These include lower educational
level, higher tobacco consumption, and reduced physical
activity, which itself is probably related to higher waist
circumference. These parameters may contribute to the
identification of people at high risk of cardiovascular
complications. Finally, treated dyslipidemia appears to
be more frequent among survivors than in patients who
died. Statistical analysis revealed that the HR associated
with statin administration was 0.64 (95 % CI, 0.46–0.89,
P < 0.01, not shown). This observation is concordant
with the reported beneficial effects, as regards mortality,
of statins when administered early after the first acute
coronary event [37, 38].
Several limitations of our study merit comment. First,
the small size of the study and the number of CAD pa-
tients with incomplete data is a limitation. Indeed, 30 %
of the CAD patients from the GENES cohort did not
have complete biological data and these patients were
thus not included in analyses. However, similar clinical
and biological characteristics were measured between
Fig. 1 Kaplan–Meier survival curves. Survival curves for the follow-up period were established around the median value of serum IF1
concentration (0.42 mg/L)
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included and non-included patients (Additional file 1:
Table S3). Second, the GENES study had a cross-
sectional design but the yearly assessment of vital status
provided a prospective frame enabling exploration of the
predictive value of markers in relation with mortality.
Nevertheless, the fact that other major coronary end-
points – recurrent infarction, revascularization proced-
ure – or cardiovascular events could not be considered
is a limitation of this study. Further, focusing on mortal-
ity only resulted in small numbers of “secondary events”.
Finally, this study was designed only with men, which
has the advantage of recording a larger number of events
than in a mixed all-gender cohort, but limited the trans-
latability of our results to women. However, although
testosterone and sex hormone binding globulin levels
have been reported to be positively correlated with
HDL-C [39], we previously found no gender-based dif-
ferences regarding the relationship between serum IF1
and HDL-C [16], suggesting that sex hormones are un-
likely to impact this relationship and that the negative
association of IF1 levels with mortality could also exist
in women.
Conclusions
In conclusion, our study identifies circulating IF1 as a
novel HDL-related biomarker strongly and independently
associated to mortality in CAD patients. This original ob-
servation will prompt new survey studies in larger all-
gender prospective cohorts in order to evaluate the value
added by IF1 over existing predictors and to assess its use-
fulness in routine clinical practice. As compared to other
emerging HDL-related biomarkers that have been also
proven to be better than HDL-C level, such as HDL-P and
subclasses measured by NMR [40, 41] or cholesterol efflux
capacity measured by cellular assays [42], measurement of
IF1 by immunoassay is technically more feasible in terms
of analytical requirements, accessibility, turnaround time,
and traceability. In the future, IF1 measurement could be
clinically useful for better prognosis in populations at high
risk or in the setting of pharmacotherapy.
Additional file
Additional file 1: Table S1. Vital status according to administered
medication in coronary artery disease patients (n = 577). Table S2.
Correlation between IF1 and HDL, measured by standard method and
NMR spectroscopy in coronary artery disease patients (n = 212). Table S3.
Comparison between coronary artery disease patients included in the
study and non-included patients. (DOCX 31 kb)
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